Multidrug Resistant Tuberculosis Clinical Trial
Official title:
Multidrug Resistant Tuberculosis Close Contacts Tracing in China
To investigate the incidence of etiologically confirmed or clinically diagnosed active tuberculosis in close contacts of MDR-TB patients.
This study is a prospective observational cohort study. MDR-TB patients from multi-centers in
China were continuously evaluated one by one, their close contacts were screened for
elibgility. All subjects were followed for the same length of time: 80 weeks after
enrollment. The symptoms and signs of tuberculosis were followed up to monitor the occurrence
of tuberculosis.
The primary objective is to investigate the incidence of etiologically confirmed or
clinically diagnosed active TUBERCULOSIS in close contacts of MDR-TB patients.
The secondary objective is to assess latent TB infection rates in close contacts of MDR-TB
patients; evaluate the high risk factors of TUBERCULOSIS in close contact population; assess
the loss rate of close contacts within 80 weeks; assess the 80-week mortality rate among
close contacts; isolate the mycobacterium tuberculosis from all patients with active
tuberculosis and analyze drug resistance to evaluate the homology and drug-resistant
transmission pattern of Mycobacterium tuberculosis.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05017324 -
Sequencing Mycobacteria and Algorithm-determined Resistant Tuberculosis Treatment Trial
|
N/A | |
Active, not recruiting |
NCT02496572 -
Effectiveness of a Simplified Short Regimen for Multidrug Resistant Tuberculosis in Uzbekistan
|
Phase 3 | |
Completed |
NCT03942354 -
Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial
|
||
Completed |
NCT02454205 -
An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis
|
Phase 2/Phase 3 | |
Recruiting |
NCT05081401 -
Innovating(IN) Shorter(S), All- Oral, Precised(P), Individualized(I) Treatment Regimen(RE) for Rifampicin Resistant Tuberculosis(INSPIRE-TB)
|
||
Completed |
NCT01856634 -
Pharmacokinetic and Safety Trial to Determine the Appropriate Dose for Pediatric Patients With Multidrug Resistant Tuberculosis
|
Phase 1 | |
Active, not recruiting |
NCT03867136 -
Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)
|
Phase 4 | |
Completed |
NCT00727844 -
Linezolid to Treat Extensively-Drug Resistant Tuberculosis
|
Phase 2 | |
Completed |
NCT01859923 -
A 6-Month Safety, Efficacy, and Pharmacokinetic (PK) Trial of Delamanid in Pediatric Participants With Multidrug Resistant Tuberculosis (MDR-TB)
|
Phase 2 | |
Active, not recruiting |
NCT04421495 -
Safety and Effectiveness of Delamanid-containing Regimen for MDR-TB Patients in China
|
Phase 4 | |
Active, not recruiting |
NCT04717908 -
Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)-PLUS
|
N/A | |
Not yet recruiting |
NCT03604848 -
NGS-Guided(G) Regimens(R) of Anti-tuberculosis(A) Drugs for the Control(C) and Eradication(E) of MDR-TB
|
N/A | |
Recruiting |
NCT02120638 -
Optimization of MDR-TB Treatment Regimen Based on the Molecular Drug Susceptibility Results of Pyrazinamide
|
Phase 3 | |
Recruiting |
NCT05534750 -
Evaluation of the Early Bactericidal Activity of Tedizolid and Linezolide Against Mycobacterium Tuberculosis (TEDITUB)
|
Phase 2 |